Recombinant Human CD30/TNFRSF8 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Binding Activity
• Format: Carrier-Free

Recombinant Human CD30/TNFRSF8 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When rhCD30 Ligand (Catalog # 1028-CL) is immobilized at 200 ng/well, the concentration of rhCD30/Fc Chimera that produces 50% of the optimal binding response is found to be approximately 1‑5 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived human CD30/TNFRSF8 protein
  

  Human CD30 (Phe19-Lys379) Accession # P28908.1	IEGRDMD	Human IgG1 (Pro100-Lys330)	6-His tag
  N-terminus			C-terminus

• Accession #: P28908.1
• N-terminal Sequence: Phe19
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: TNFRSF8
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Binding Activity
• Theoretical MW: 66 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 100-125 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CD30/TNFRSF8 Fc Chimera Protein, CF

• CD30 antigen
• CD30
• CD30KI-1
• CD30L receptor
• cytokine receptor CD30
• D1S166EKi-1
• Ki-1 antigen
• Lymphocyte activation antigen CD30
• TNFRSF8
• tumor necrosis factor receptor superfamily member 8
• tumor necrosis factor receptor superfamily, member 8

Background

CD30, also known as Ki-1 antigen and TNFRSF8, is a 120 kDa type I transmembrane glycoprotein belonging to the TNF receptor superfamily (1, 2). Mature human CD30 consists of a 361 amino acid (aa) extracellular domain (ECD) with six cysteine-rich repeats, a 28 aa transmembrane segment, and a 188 aa cytoplasmic domain (3). In contrast, mouse and rat CD30 lack 90 aa of the ECD and contain only three cysteine-rich repeats. Within common regions of the ECD, human CD30 shares 53% and 49% aa sequence identity with mouse and rat CD30, respectively. Alternate splicing of human CD30 generates an isoform that includes only the C‑terminal 132 aa of the cytoplasmic domain. CD30 is normally expressed on antigen-stimulated Th cells and B cells (4 - 6). However, it is upregulated in Hodgkin’s disease (on Reed-Sternberg cells), other lymphomas, chronic inflammation, and autoimmunity (7). CD30 binds to CD30 Ligand/TNFSF8 which is expressed on activated Th cells, monocytes, granulocytes and medullary thymic epithelial cells (1, 5). CD30 signaling costimulates antigen-induced Th0 and Th2 proliferation and cytokine secretion but favors a Th2-biased immune response (8). In the absence of antigenic stimulation, it can still induce T cell expression of IL-13 (9). CD30 contributes to thymic negative selection by inducing the apoptotic cell death of CD4+CD8+ T cells (10, 11). In B cells, CD30 ligation promotes cellular proliferation and antibody production in addition to the expression of CXCR4, CCL3, and CCL5 (5, 12). An 85 ‑ 90 kDa soluble form of CD30 is shed from the cell surface by TACE-mediated cleavage (13, 14). Soluble CD30 retains the ability to bind CD30 Ligand and functions as an inhibitor of normal CD30 signaling (15).

1. Kennedy, M.K. et al. (2006) Immunology 118:143.
2. Tarkowski, M. (2003) Curr. Opin. Hematol. 10:267.
3. Durkop, H. et al. (1992) Cell 68:421.
4. Hamann, D. et al. (1996) J. Immunol. 156:1387.
5. Shanebeck, S.D. et al. (1995) Eur. J. Immunol. 25:2147.
6. Gruss, H.-J. et al. (1994) Blood 83:2045.
7. Oflzoglu E. et al. (2009) Adv. Exp. Med. Biol. 647:174.
8. Del Prete, G. et al. (1995) J. Exp. Med. 182:1655.
9. Harlin, H. et al. (2002) J. Immunol. 169:2451.
10. Amakawa, R. et al. (1996) Cell 84:551.
11. Chiarle, R. et al. (1999) J. Immunol. 163:194.
12. Vinante, F. et al. (2002) Blood 99:52.
13. Hansen, H.P. et al. (1995) Int. J. Cancer 63:750.
14. Hansen, H.P. et al. (2000) J. Immunol. 165:6703.
15. Hargreaves, P.G. and A. Al-Shamkhani (2002) Eur. J. Immunol. 32:163.

Publications for CD30/TNFRSF8 (813-CD)(2)

Publications using 813-CD

• R Wang, L Li, S Zhang, Y Li, X Wang, Q Miao, Y Zhen A novel enediyne-integrated antibody-drug conjugate shows promising anti-tumor efficacy against CD30+ lymphomas Mol Oncol, 2018-01-26;0(0):. 2018-01-26 [PMID: 29316337] (Human)
• Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, Zhang HF, Davis T, Keler T, Diehl V, Graziano RF, Engert A The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood, 2003-07-24;102(10):3737-42. 2003-07-24 [PMID: 12881320] (ELISA (Capture), Surface Plasmon Resonance, Human)

Bioinformatics

• Gene Symbol: TNFRSF8
• Uniprot:
  • P28908.1()